The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after identifying a safety concern.

Novavax (NASDAQ:NVAX) shares climbed 12% premarket on Monday after the U.S. FDA lifted clinical hold on the investigational new drug application for the pharma firm’s COVID-19-Influenza ...

The Food and Drug Administration halted Novavax's trial of a combination vaccine for COVID and influenza, as well as a standalone flu shot, after a participant suffered a serious adverse event ...

The FDA has put Novavax's trial of an experimental COVID-flu vaccine combination on hold after one person who received the shot reported nerve damage, the company said Wednesday.

Zinger Key Points FDA places a clinical hold on Novavax's COVID-19-influenza vaccine trials due to a serious adverse event in a Phase 2 participant.

Novavax announced that the U.S. Food and Drug Administration has placed a clinical hold on Novavax’s Investigational New Drug, or IND, application for its COVID-19-Influenza Combination, or CIC ...

Novavax shares plummet 30% as FDA places clinical hold on COVID-19 and influenza combination vaccine due to serious adverse event.

That deal saw Novavax retain the rights to its combo COVID-flu vaccine, while Sanofi has the sole license to use Novavax’s adjuvanted COVID-19 vaccine in combination with Sanofi's own flu ...

US News: The US Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines af.

Sanofi said the clinical hold has "nothing to do with" its partnership with Novavax. Outside of the agreement, the companies can individually develop their own flu-COVID vaccines and other ...

The U.S. Food and Drug Administration has put on hold a trial of Novavax's COVID-influenza and its standalone flu vaccines after a participant who took the combination shot reported nerve damage ...